Effect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma
Wang-Zhong Li,Xing Lv,Dan Hu,Shu-Hui Lv,Guo-Ying Liu,Hu Liang,Yan-Fang Ye,Wen Yang,Han-Xiong Zhang,Tai-Ze Yuan,De-Shen Wang,Nian Lu,Liang-Ru Ke,Wu-Bing Tang,Li-Hua Tong,Zhi-Jie Chen,Ting Liu,Ka-Jia Cao,Hao-Yuan Mo,Ling Guo,Chong Zhao,Ming-Yuan Chen,Qiu-Yan Chen,Pei-Yu Huang,Rui Sun,Fang Qiu,Dong-Hua Luo,Lin Wang,Yi-Jun Hua,Lin-Quan Tang,Chao-Nan Qian,Hai-Qiang Mai,Xiang Guo,Yan-Qun Xiang,Wei-Xiong Xia
DOI: https://doi.org/10.1001/jamaoncol.2022.0122
IF: 33.006
2022-03-24
JAMA Oncology
Abstract:Question Does chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) improve failure-free survival compared with cisplatin and fluorouracil (PF) as induction treatment prior to concurrent chemoradiotherapy for patients with stage IVA to IVB nasopharyngeal carcinoma?Findings In this phase 3 randomized clinical trial of 238 patients with stage IVA to IVB nasopharyngeal carcinoma, induction chemotherapy with 2 cycles of TPC followed by 2 cycles of concurrent chemoradiotherapy resulted in a statistically significant improvement in failure-free survival compared with 2 cycles of PF followed by 2 cycles of concurrent chemoradiotherapy, with no increase in the toxicity profile.Meaning Induction chemotherapy with TPC is more efficacious than that with PF for patients with stage IVA to IVB nasopharyngeal carcinoma.Importance Induction chemotherapy added to concurrent chemoradiotherapy significantly improves survival for patients with locoregionally advanced nasopharyngeal carcinoma, but the optimal induction regimen remains unclear.Objective To determine whether induction chemotherapy with paclitaxel, cisplatin, and capecitabine (TPC) improves survival vs cisplatin and fluorouracil (PF) prior to chemoradiotherapy for patients with stage IVA to IVB nasopharyngeal carcinoma.Design, Setting, and Participants This randomized, open-label, phase 3 clinical trial recruited 238 patients at 4 hospitals in China from October 20, 2016, to August 29, 2019. Patients were 18 to 65 years of age with treatment-naive, nonkeratinizing stage IVA to IVB nasopharyngeal carcinoma and an Eastern Cooperative Oncology Group performance status of 0 to 1.Interventions Patients were randomly assigned (1:1) to receive induction chemotherapy with two 21-day cycles of TPC (intravenous paclitaxel [150 mg/m2, day 1], intravenous cisplatin [60 mg/m2, day 1], and oral capecitabine [1000 mg/m2 orally twice daily, days 1-14]) or PF (intravenous cisplatin [100 mg/m2, day 1] and fluorouracil [800 mg/m2 daily, days 1-5]), followed by chemoradiotherapy.Main Outcomes and Measures The primary end point was failure-free survival in the intention-to-treat population. Secondary end points included distant metastasis–free survival, locoregional relapse–free survival, overall survival, tumor response, and safety.Results Overall, 238 eligible patients (187 men [78.6%]; median age, 45 years [range, 18-65 years]) were randomly assigned to receive TPC (n = 118) or PF (n = 120). The median follow-up duration was 48.4 months (IQR, 39.6-53.3 months). Failure-free survival at 3 years was 83.5% (95% CI, 77.0%-90.6%) in the TPC group and 68.9% (95% CI, 61.1%-77.8%) in the PF group (stratified hazard ratio [HR] for recurrence or death, 0.47; 95% CI, 0.28-0.79; P = .004). Induction with the TPC regimen resulted in a significant reduction in the risk of distant metastases (stratified HR, 0.49 [95% CI, 0.24-0.98]; P = .04) and locoregional recurrence (stratified HR, 0.40 [95% CI, 0.18-0.93]; P = .03) compared with the PF regimen. However, there was no effect on early overall survival (stratified HR, 0.45 [95% CI, 0.17-1.18]; P = .10). The incidences of grade 3 to 4 acute adverse events and late-onset toxicities were 57.6% (n = 68) and 13.6% (16 of 118), respectively, in the TPC group and 65.8% (n = 79) and 17.9% (21 of 117), respectively, in the PF group. One treatment-related death occurred in the PF group.Conclusions and Relevance This randomized clinical trial found that induction chemotherapy with 2 cycles of TPC for patients with stage IVA to IVB nasopharyngeal carcinoma improved failure-free survival compared with 2 cycles of PF, with no increase in the toxicity profile.Trial Registration ClinicalTrials.gov Identifier: NCT02940925
oncology